The science of vaccine adjuvants: Advances in TLR4 ligand adjuvants

Current Opinion in Immunology

Volumn 41, Issue , 2016, Pages 85-90

  Reed, Steven G ^a   Hsu, Fan Chi ^a   Carter, Darrick ^a   Orr, Mark T ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; IMMUNOLOGICAL ADJUVANT; LIGAND; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; VACCINE; GLYCOLIPID;

ADAPTIVE IMMUNITY; ANTIGEN FUNCTION; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VACCINE PRODUCTION; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; SYNTHESIS;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; GLYCOLIPIDS; HUMANS; LIGANDS; TOLL-LIKE RECEPTOR 4; VACCINES;

EID: 84977112074     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.06.007     Document Type: Review

References (43)

1. Johnson A.G., Gaines S., Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med 1956, 103:225-246.
2. Johnson D.A. TLR4 agonists as vaccine adjuvants: a chemist's perspective. Expert Rev Vaccines 2013, 12:711-713.
3. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8:235-247.
4. Schwarz T.F. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 2009, 26:983-998.
5. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., Laughlin E.M., Duthie M.S., Fox C.B., Carter D., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
6. Orr M.T., Fox C.B., Baldwin S.L., Sivananthan S.J., Lucas E., Lin S., Phan T., Moon J.J., Vedvick T.S., Reed S.G., et al. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 2013, 172:190-200.
7. Wiley S.R., Raman V.S., Desbien A., Bailor H.R., Bhardwaj R., Shakri A.R., Reed S.G., Chitnis C.E., Carter D. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 2011, 3. 93ra69.
8. Desbien A.L., Van Hoeven N., Reed S.J., Casey A.C., Laurance J.D., Baldwin S.L., Duthie M.S., Reed S.G., Carter D. Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses. Biotechniques 2013, 54:345-348.
9. Baldwin S.L., Fox C.B., Pallansch M.A., Coler R.N., Reed S.G., Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011, 29:644-649.
10. Coler R.N., Duthie M.S., Hofmeyer K.A., Guderian J., Jayashankar L., Vergara J., Rolf T., Misquith A., Laurance J.D., Raman V.S., et al. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunol 2015, 4:e35.
11. Treanor J.J., Essink B., Hull S., Reed S., Izikson R., Patriarca P., Goldenthal K.L., Kohberger R., Dunkle L.M. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 2013, 31:5760-5765.
12. Desbien A.L., Reed S.J., Bailor H.R., Dubois Cauwelaert N., Laurance J.D., Orr M.T., Fox C.B., Carter D., Reed S.G., Duthie M.S. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-gamma. Eur J Immunol 2015, 45:407-417.
13. Fox C.B., Mulligan S.K., Sung J., Dowling Q.M., Fung H.W., Vedvick T.S., Coler R.N. Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes. Int J Nanomed 2014, 9:1367-1377.
14. Lambert S.L., Yang C.F., Liu Z., Sweetwood R., Zhao J., Cheng L., Jin H., Woo J. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS One 2012, 7:e51618.
15. Santini-Oliveira M., Coler R.N., Parra J., Veloso V., Jayashankar L., Pinto P.M., Ciol M.A., Bergquist R., Reed S.G., Tendler M. Schistosomiasis vaccine candidate Sm14/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults. Vaccine 2016, 34:586-594.
16. Schneider L.P., Schoonderwoerd A.J., Moutaftsi M., Howard R.F., Reed S.G., de Jong E.C., Teunissen M.B. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012, 30:4216-4224.
17. Misquith A., Fung H.W., Dowling Q.M., Guderian J.A., Vedvick T.S., Fox C.B. In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf B Biointerfaces 2014, 113:312-319.
18. Windish H.P., Duthie M.S., Misquith A., Ireton G., Lucas E., Laurance J.D., Bailor R.H., Coler R.N., Reed S.G. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 2011, 29:7842-7848.
19. Cha S.B., Kim W.S., Kim J.S., Kim H., Kwon K.W., Han S.J., Cho S.N., Coler R.N., Reed S.G., Shin S.J. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine 2016, 34:2179-2187.
20. Lambert S.L., Aslam S., Stillman E., MacPhail M., Nelson C., Ro B., Sweetwood R., Lei Y.M., Woo J.C., Tang R.S. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLOS ONE 2015, 10:e0119509.
21. Orr M.T., Duthie M.S., Windish H.P., Lucas E.A., Guderian J.A., Hudson T.E., Shaverdian N., O'Donnell J., Desbien A.L., Reed S.G., et al. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol 2013, 43:2398-2408.
22. Park B.S., Allen D.N., Barney S.J., Ringdahl E.N., Mayfield J. Structure of attention in children with traumatic brain injury. Appl Neuropsychol 2009, 16:1-10.
23. Van Hoeven N., Joshi S.W., Nana G.I., Bosco-Lauth A., Fox C., Bowen R.A., Clements D.E., Martyak T., Parks D.E., Baldwin S., et al. A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage West Nile virus vaccine antigen in multiple formulations. PLOS ONE 2016, 11:e0149610.
24. Alloatti A., Kotsias F., Pauwels A.M., Carpier J.M., Jouve M., Timmerman E., Pace L., Vargas P., Maurin M., Gehrmann U., et al. Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens. Immunity 2015, 43:1087-1100.
25. Skeiky Y.A., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M., Badaro R., Trinchieri G., Reed S.G. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995, 181:1527-1537.
26. Probst P., Skeiky Y.A., Steeves M., Gervassi A., Grabstein K.H., Reed S.G. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 1997, 27:2634-2642.
27. Wang Y., Su L., Morin M.D., Jones B.T., Whitby L.R., Surakattula M.M., Huang H., Shi H., Choi J.H., Wang K.W., et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A 2016, 113:E884-E893.
28. Kelley S.L., Lukk T., Nair S.K., Tapping R.I. The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket. J Immunol 2013, 190:1304-1311.
29. Ranoa D.R., Kelley S.L., Tapping R.I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem 2013, 288:9729-9741.
30. Jin M.S., Lee J.O. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008, 29:182-191.
31. Tan Y., Zanoni I., Cullen T.W., Goodman A.L., Kagan J.C. Mechanisms of toll-like receptor 4 endocytosis reveal a common immune-evasion strategy used by pathogenic and commensal bacteria. Immunity 2015, 43:909-922.
32. Ma C.Y., Chang W.E., Shi G.Y., Chang B.Y., Cheng S.E., Shih Y.T., Wu H.L. Recombinant thrombomodulin inhibits lipopolysaccharide-induced inflammatory response by blocking the functions of CD14. J Immunol 2015, 194:1905-1915.
33. Nymo S., Gustavsen A., Nilsson P.H., Lau C., Espevik T., Mollnes T.E. Human endothelial cell activation by Escherichia coli and Staphylococcus aureus is mediated by TNF and IL-1beta secondarily to activation of C5 and CD14 in whole blood. J Immunol 2016, 196:2293-2299.
34. Wilson N.S., Duewell P., Yang B., Li Y., Marsters S., Koernig S., Latz E., Maraskovsky E., Morelli A.B., Schnurr M., et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol 2014, 192:3259-3268.
35. Vono M., Taccone M., Caccin P., Gallotta M., Donvito G., Falzoni S., Palmieri E., Pallaoro M., Rappuoli R., Di Virgilio F., et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A 2013, 110:21095-21100.
36. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
37. Jounai N., Kobiyama K., Takeshita F., Ishii K.J. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol 2012, 2:168.
38. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011, 29:707-735.
39. Didierlaurent A.M., Collignon C., Bourguignon P., Wouters S., Fierens K., Fochesato M., Dendouga N., Langlet C., Malissen B., Lambrecht B.N., et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014, 193:1920-1930.
40. Larena M., Holmgren J., Lebens M., Terrinoni M., Lundgren A. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. J Immunol 2015, 194:3829-3839.
41. Pantel A., Cheong C., Dandamudi D., Shrestha E., Mehandru S., Brane L., Ruane D., Teixeira A., Bozzacco L., Steinman R.M., et al. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo. Eur J Immunol 2012, 42:101-109.
42. Cantisani R., Pezzicoli A., Cioncada R., Malzone C., De Gregorio E., D'Oro U., Piccioli D. Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells. J Immunol 2015, 194:1717-1725.
43. Gaya M., Castello A., Montaner B., Rogers N., Reis e Sousa C., Bruckbauer A., Batista F.D. Host response, inflammation-induced disruption of SCS macrophages impairs B cell responses to secondary infection. Science 2015, 347:667-672.